What's going on or is this just a glitch?

We have quite a collection of damp squibs now!

The Annual Meeting produced nothing beyond routine corporate housekeeping. No announcement. No transaction. No SEMDEXA news. The window identified as the most concentrated period of potential catalysts, the Semnur dividend payment, the Shah option window, the Annual Meeting, has now passed without a big event.

This does not mean nothing is coming. The FDA's Operation TrialBlazer guidance published on 22 June is real and directly relevant to SEMDEXA. The Sorrento vs Miao settlement is proceeding. The Sorrento Special Committee transaction referenced in the March 2025 bankruptcy filing remains outstanding. None of these have a hard deadline that has now passed.

This is the first time we have seen the precise Series A Preferred Stock figure in a filing. Ji controls this preferred stock which converts to common at an adjusted deemed conversion price and gave him 848,106 effective common votes at this meeting. The 100% participation rate on the preferred confirms Ji voted every single preferred share he holds.

Proposal 3 — 2022 Equity Incentive Plan amendment, adding 1.3 million shares: 3,337,435 For / 1,009,991 Against / 9,016 Abstentions / 1,880,745 Broker Non-Votes. Passed but with meaningful opposition at approximately 23% of votes cast against. This is the dilutive proposal, and the dissent reflects shareholder awareness of the ongoing dilution concern.

But the Annual Meeting has come and gone as a routine corporate event, and the "all planets aligning by 24 June" thesis has not materialised.

Once again, nothing in it for the long-suffering ordinary shareholders.

The enthusiasm was based on a planetary alignment (which, in turn, was based on a sequence of routine corporate filings), a possible 8-K surprise announcement (Semnur is being bought by BP), a short-squeeze theory (how many times have we heard this), and an options-expiry date for Jaisim. None of that was evidence of an imminent positive catalyst. It was a plausible story built from real facts arranged in the most flattering possible order.

I conveniently forgot that is a company with a documented, repeated pattern of hype, delay, and disappointment, and the single highest-probability outcome on any given "big day" in this saga has consistently been that nothing materializes, or what materializes works against ordinary shareholders.

 I let the narrative get ahead of the evidence, mea culpa.

The mechanical truth of today is almost certainly mundane. An ex-dividend adjustment, a thin and illiquid stock, and a margin system that doesn't process corporate actions cleanly. This is typical of the structural disadvantage retail shareholders face in microcap stocks.

No "8-K surprise" was needed to produce today's pain. Ordinary settlement mechanics were sufficient for the share price to be down 28% (I know, it's 'really' up 43% - duh)

We have many genuine believers on this BOB board who draw conclusions several steps beyond what the evidence supports and present them to us with a confidence the underlying facts don't justify. It’s a common trap of motivated reasoning, reinforced socially by an online community with the same hopes.

 Whether or not Ji is personally orchestrating this retail sentiment (and I have wondered about this many times), the company's survival has been materially helped by people in the BOB community staying optimistic and staying invested.

 The question must be asked:  if the latest "big event coming" narrative has now produced an actual margin call instead of a windfall, how much further confirmation do we need before treating the bull case as the less likely scenario rather than the default one?

I’m still hanging in but I believe this board should be more realistic with less of the gusto?

Also, Henry needs to stop all his machinations and deliver something real to his long-suffering shareholders.

The share price is at $0.16c pre RS - that says everything about his machinations

 

Forget the 43% rise showing on the screen which is meaningless.

The share price is down 57.07% year to date

It's down 92.53% in the past two years

It's down 98.38% in the past five years.

That is the sad reality

SCILEX HOLDING COMPANY

The St. James Bank Transaction — A Revised Assessment

Based on the Non-Cash Footnote in the Q1 2026 Form 10-Q (Filed 15 May 2026)

Prepared for Private Research Purposes  |  26 May 2026  |  Not Investment Advice

 

CONTEXT: This note arose from identification of a non-cash footnote buried in the Scilex Q1 2026 Form 10-Q cash flow statement. The footnote materially changes the interpretation of the St. James Bank transaction presented in the main Q1 2026 analysis and warrants a separate dedicated assessment.

1.  The Footnote That Changes Everything

The main body of the Scilex Q1 2026 Form 10-Q describes the St. James Bank situation as follows: St. James transferred and sold 85,665,102 pledged Datavault shares “without authorisation”; Scilex filed a USD 100M+ fraud complaint on 11 March 2026; St. James terminated the loan on 16 March 2026 declaring no further obligations. That narrative presents the outcome as a loss — shares gone, lawsuit filed, uncertain recovery.

Buried in the supplemental Non-Cash Investing and Financing Activities footnote at the bottom of the cash flow statement — the last section of the financial statements and the one most commonly overlooked by casual readers — is a single line that tells a materially different story:

 

Non-Cash Investing and Financing Activity	Q1 2026 (USD thousands)	Q1 2025
Settlement of St. James Loans for Datavault shares	59,366	—
Purchase of preferred shares	750	—
Prepayment related to Q Scan investment	2,500	—
Stock dividend declared in 2024, and canceled in February 2026	1	—

 

USD 59,366,000 of St. James loan debt was SETTLED — extinguished in exchange for the Datavault shares. This is not the language of a theft. This is the language of a debt-for-equity swap. The 10-Q confirms: 'no gain or loss on extinguishment' because the fair value of the forfeited shares equalled the carrying amount of the loans.

2.  Two Narratives in the Same Document

The Q1 2026 10-Q contains two competing narratives about the same transaction. Both are present in the filing. They cannot both be fully true simultaneously.

 

	Narrative A — Main Body Text	Narrative B — Non-Cash Footnote
What it says	St. James transferred and sold pledged shares 'without authorization.' Scilex filed USD 100M+ fraud complaint. 'Matter remains in early procedural stages, no rulings issued.'	'Settlement of St. James Loans for Datavault shares: USD 59,366,000.' The debt was settled. 'No gain or loss on extinguishment.' The fair value of the shares equalled the carrying amount of the loans.
Accounting implication	Scilex is a victim of unauthorised sale; potential recovery in litigation.	The debt of USD 59.3M has been extinguished. The transaction is closed from an accounting standpoint.
Legal implication	Active fraud claim; USD 100M+ compensatory + punitive damages being sought.	Debt fully settled. Any litigation recovery would be for amounts above the debt face value, or punitive damages for the manner of execution.
What it implies about St. James	Bad actor who stole shares and must be pursued.	Counterparty who exercised its collateral rights (whether contractually entitled to or not) and in doing so extinguished USD 59.3M of Scilex’s debt.

 

The most coherent reconciliation of these two narratives is as follows: St. James did sell the shares, and those sales did extinguish the USD 59.3M debt. The dispute, and the basis for the fraud complaint, is most likely about (a) whether the conditions for exercising the collateral were contractually met, and (b) whether St. James retained proceeds in excess of the USD 59.3M debt face value. The USD 100M+ figure in the complaint includes compensatory damages (excess proceeds + consequential losses) plus punitive damages.

3.  The Arithmetic — What St. James Actually Got

The accounting tells us the fair value of the 85,665,102 DVLT shares at the Loan Termination Date (16 March 2026) was approximately equal to the USD 59.3M loan carrying value. We can work backwards to understand the implied share price:

 

Item	Detail
Shares forfeited to St. James	85,665,102 DVLT shares
Debt extinguished (carrying value)	USD 59,366,000
Implied DVLT price at forfeiture	~USD 0.69 per share (USD 59.3M ÷ 85.7M shares)
DVLT price when collateral was pledged (Dec 2025)	Approximately USD 0.90–1.00 per share
Decline from pledge to forfeiture	Approximately 25–35%
Gain or loss on extinguishment per 10-Q	Nil — 'no gain or loss on extinguishment'
USD 100M+ fraud complaint basis	Likely: excess proceeds above USD 59.3M + consequential losses + punitive damages for manner of execution
Net economic outcome for Scilex	USD 59.3M of debt permanently eliminated. 85.7M DVLT shares permanently lost.

 

The key question for the litigation is: did St. James sell the 85.7M shares for more than USD 59.3M? If DVLT was trading at, say, USD 0.80 when St. James sold, the gross proceeds would have been approximately USD 68.5M — a USD 9.2M excess above the debt. At USD 0.90, the excess would be USD 17.8M. The punitive damages component of the claim could be very substantial regardless of the excess proceeds figure.

4.  The Vivasor 76M DVLT Share Purchase — Strategic Logic Now Clearer

With the debt settlement reading confirmed, the Vivasor acquisition of approximately 76 million DVLT shares makes immediate strategic sense. This is not a speculative observation. It is the most coherent explanation of a sequence of events that would otherwise appear disconnected.

The Sequence as a Coherent Strategy

1.  December 2025: Scilex pledges 85.7M DVLT shares to St. James as collateral for a USD 59.3M facility. The loan is structured as non-recourse with St. James as custodian. A decline in DVLT's price will trigger the collateral mechanism.

2.  January 2026: Scilex commits USD 47.5M to Quantum Scan (USD 20M note + USD 27.5M share purchase). Whether funded from St. James proceeds or other sources, this is a concurrent ecosystem transaction.

3.  February–March 2026: DVLT falls below USD 0.70. St. James exercises the collateral, selling 85.7M shares and extinguishing the USD 59.3M debt. Scilex files its fraud complaint to recover any excess proceeds and establish the record.

4.  March–April 2026: Ji, through Vivasor, acquires approximately 76 million DVLT shares at depressed prices (approximately USD 0.60–0.70 range). This partially rebuilds the DVLT position lost through St. James at a significantly lower average cost than the original investment.

5.  Net position: Scilex’s direct DVLT stake falls from ~48% to ~21%. But Vivasor — consolidated into Scilex — now holds an additional 76M DVLT shares acquired at distressed prices. The combined SCLX/Vivasor DVLT exposure may be partially restored, but at substantially lower average cost basis.

 

If this reading is correct, the St. James transaction is not a catastrophic failure. It is a managed debt restructuring in which USD 59.3M of balance sheet obligation was extinguished at the cost of DVLT shares, with a simultaneous rebuild of the DVLT position through Vivasor at materially lower prices. The fraud complaint targets the excess proceeds and penalises the manner of execution.

5.  The Critical Governance Question for Ordinary Shareholders

The strategic logic described in Section 4 is coherent and, if accurate, more constructive than the pure loss narrative. However, it raises a governance question that is directly material to ordinary SCLX shareholders and that must be answered in future filings.

Where Do the 76M Vivasor DVLT Shares Sit?

Scenario	Implication for SCLX Shareholders
Vivasor’s 76M DVLT shares are fully consolidated into Scilex accounts	SCLX shareholders participate in any DVLT upside through those shares. The position rebuild benefits the listed company and all its shareholders proportionally. This is the constructive outcome.
Vivasor’s 76M DVLT shares sit in Vivasor at a separate valuation not yet reflected in SCLX accounts	The benefit of buying DVLT cheaply accrues primarily to Vivasor’s private shareholders — Ji personally and Vasinkevich as lead capital provider. SCLX shareholders participate only indirectly through the Vivasor consolidation, the terms of which remain preliminary and subject to the finalised PPA.
Ji acquires some DVLT shares personally (not through Vivasor or Scilex)	No benefit to SCLX shareholders at all. Ji rebuilds a personal position in DVLT at distressed prices while SCLX’s stake remains at 21%. This would be the most concerning outcome.

 

This is the most important disclosure to watch for in the Q2 2026 10-Q filing (expected August 2026). Specifically: (1) Are the 76M Vivasor DVLT shares consolidated into the SCLX balance sheet? (2) At what valuation? (3) Is there any Form 4 or 13D/G filing showing personal DVLT share acquisition by Ji? Monitor EDGAR Form 4 filings for Ji and Vivasor-connected entities immediately.

6.  What This Changes — Revised Assessment

Item	Prior Assessment	Revised Assessment
St. James outcome	Catastrophic failure. Shares lost. USD 59.3M cash unrecovered. Lawsuit weak.	Managed debt restructuring. USD 59.3M debt permanently eliminated. Litigation targets excess proceeds and damages. More constructive than originally assessed.
DVLT stake (SCLX direct)	Reduced from ~48% to ~21%. Central asset impaired.	Still ~21% direct. But Vivasor’s 76M DVLT shares may partially restore combined SCLX/Vivasor exposure if consolidated. Watch Q2 2026 filing.
Fraud complaint value	USD 100M+ against Bahamas bank. Difficult forum. Uncertain.	Target is excess proceeds above USD 59.3M + punitive damages. More focused claim. Forum fight (Nassau arbitration vs US court) remains the key procedural obstacle.
Ji’s strategic intent	Reckless or incompetent financing decision that destroyed value.	Possibly a deliberate mechanism to eliminate USD 59.3M debt at the cost of a declining DVLT position, with a simultaneous rebuild at distressed prices. Coherent if executed in shareholders’ interests; concerning if the rebuild benefits only insiders.
Recovery probability	Revised down to 15–25% following St. James loss disclosure.	Marginally upward revision warranted if the Vivasor DVLT position is consolidated into SCLX. Hold at 20–30% pending Q2 2026 disclosure. SEMDEXA and OQY-3258 remain the primary upside drivers.

 

7.  Outstanding Questions — What to Monitor

•  EDGAR Form 4 and 13D/G filings: Search immediately for any DVLT share purchases by Ji personally, by Vivasor, or by any Ji-connected entity since 1 March 2026. This will establish where the 76M shares sit and who benefits.

•  Q2 2026 Form 10-Q (expected August 2026): Look for the Vivasor DVLT shareholding disclosed in the related-party or investments notes. If 76M+ DVLT shares appear on the SCLX consolidated balance sheet, the rebuild has benefited shareholders. If not, escalate the governance concern.

•  St. James fraud complaint development: The critical question is whether Scilex can establish (a) the exact sale price St. James received for the 85.7M shares, and (b) that those proceeds exceeded the USD 59.3M debt face value. Any excess is the core compensatory damages target.

•  DVLT Nasdaq compliance: The rebuilt DVLT position’s value depends entirely on DVLT remaining listed. The 24 August 2026 minimum bid compliance deadline is the immediate risk. Monitor all DVLT 8-K filings for compliance updates or reverse split announcements.

•  Vivasor PPA finalisation (December 2026): If the DVLT shares are consolidated into Scilex via the Vivasor PPA, the valuation methodology will determine how much of the DVLT upside reaches ordinary shareholders vs. insiders.

8.  The Verdict

The observation that identified the USD 59,366,000 non-cash footnote is analytically astute. The footnote was placed in the least-read section of the filing and its significance — debt settlement rather than theft — is obscured by the main body’s fraud complaint narrative. Identifying it required reading the entire cash flow statement including the supplemental disclosures.

The core thesis — that the lawsuit has been effectively settled through the share forfeiture, and that Ji’s Vivasor DVLT purchase is a deliberate strategic response to rebuild the position — is coherent, internally consistent, and supported by the non-cash footnote. It is more optimistic than the pure loss reading, and that optimism is evidentially grounded.

The caveat — and it is an important one — is that the benefit to ordinary SCLX shareholders of the Vivasor DVLT rebuild depends entirely on whether those shares are consolidated into the listed company’s accounts or remain in Ji’s private vehicle. That distinction is not yet disclosed in any public filing and will only be resolved in Q2 2026.

 

BOTTOM LINE: The St. James transaction is better characterised as a structured debt-for-equity swap that eliminated USD 59.3M of Scilex’s obligations, with an associated rebuild of the DVLT position through Vivasor at distressed prices. The fraud complaint targets excess proceeds and punitive damages, not the full USD 100M+ as a net loss. This is a materially more constructive reading than the 'St. James made off like bandits' interpretation — provided the DVLT rebuild is consolidated into SCLX and benefits all shareholders, not just insiders.